{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:52:30Z","timestamp":1770277950389,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.leukres.2011.12.018","type":"journal-article","created":{"date-parts":[[2012,1,31]],"date-time":"2012-01-31T10:22:25Z","timestamp":1328005345000},"page":"509-513","source":"Crossref","is-referenced-by-count":17,"title":["The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line"],"prefix":"10.1016","volume":"36","author":[{"given":"Hongyun","family":"Xing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.12.018_bib0005","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALL-XII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.018_bib0010","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/asheducation-2005.1.118","article-title":"Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"1","author":"Ottmann","year":"2005","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.leukres.2011.12.018_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(04)91001-9","article-title":"Imatinib as a paradigm of targeted therapies","volume":"91","author":"Druker","year":"2004","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.leukres.2011.12.018_bib0020","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00001622-200211000-00005","article-title":"Mechanisms of resistance to imatinib mesylate in BCR-ABL1-positive leukemias","volume":"14","author":"Nimmanapalli","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.leukres.2011.12.018_bib0025","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/cncr.22631","article-title":"Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"109","author":"Ottmann","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.12.018_bib0030","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL1 gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.leukres.2011.12.018_bib0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL1 kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2011.12.018_bib0040","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.018_bib0045","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.018_bib0050","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.bbrc.2009.12.086","article-title":"Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib","volume":"391","author":"Ozaki","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.leukres.2011.12.018_bib0055","doi-asserted-by":"crossref","first-page":"e6124","DOI":"10.1371\/journal.pone.0006124","article-title":"ERK2, but not ERK1, mediates acquired and denovo resistance to imatinib mesylate: implication for CML therapy","volume":"4","author":"Aceves-Luquero","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2011.12.018_bib0060","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells","volume":"103","author":"Chu","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.018_bib0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2006.06161.x","article-title":"BCR-ABL1 activates STAT3 via JAK and MEK pathways in human cells","volume":"134","author":"Coppo","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2011.12.018_bib0070","doi-asserted-by":"crossref","first-page":"34227","DOI":"10.1074\/jbc.M402290200","article-title":"A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2","volume":"279","author":"Dai","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2011.12.018_bib0075","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","article-title":"Kinase domain mutations of BCR-ABL1 frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.018_bib0080","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"Le Coutre","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.018_bib0085","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.018_bib0090","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","article-title":"hOCT 1 and resistance to imatinib","volume":"106","author":"Crossman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.018_bib0095","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL1 kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.12.018_bib0100","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cncr.23666","article-title":"Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL1 kinase inhibitors","volume":"113","author":"Jones","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.12.018_bib0105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood.V112.11.702.702","article-title":"Minimal residual disease and mutational status prior to and after SCT for patients with philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"112","author":"Pfeifer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.018_bib0110","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.018_bib0115","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of BCR-ABL1 inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.12.018_bib0120","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel AB kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.leukres.2011.12.018_bib0125","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.12.018_bib0130","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL1 inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.018_bib0135","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/cncr.20026","article-title":"Mammalian target of rapamycin inhibition as therapy for hematologic malignancies","volume":"100","author":"Panwalkar","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.12.018_bib0140","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.leukres.2008.07.023","article-title":"Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor","volume":"33","author":"Hirase","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.12.018_bib0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1523-1755.2001.00460.x","article-title":"Rapamycin in transplantation: a review of the evidence","volume":"59","author":"Saunders","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.leukres.2011.12.018_bib0150","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(89)90417-0","article-title":"Rapamycin for immunosuppression in organ allografting","volume":"2","author":"Calne","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2011.12.018_bib0155","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1126\/science.1702904","article-title":"Chemistry and biology of the immunophilins and their immunosuppressive ligands","volume":"251","author":"Schreibers","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.leukres.2011.12.018_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/bbrc.1994.2140","article-title":"A putative sirolimus (rapamycin) effector protein","volume":"203","author":"Chen","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.leukres.2011.12.018_bib0165","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A mammalian protein targeted by G1-arresting rapamycin\u2013receptor complex","volume":"369","author":"Brown","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2011.12.018_bib0170","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/sj.leu.2402526","article-title":"Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lym phoblastic leukemia: the JALSG-ALL93 study","volume":"16","author":"Takeuchi","year":"2002","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611006096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611006096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T12:31:39Z","timestamp":1593606699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212611006096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0145212611006096"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.12.018","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}